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Why Is This Necessary?
•

As the vaccine becomes approved for emergency use by the FDA, patients
are bringing questions to their visits

•

With an abundance of information online and in the news, it can be difficult
to boil down to the basics and know that the information you are reading is
accurate

•

Time spent discussing the COVID vaccine takes away from time discussing
other chronic health conditions

•

With information about the vaccine constantly evolving, distributing
material with accurate information as well as trustworthy sites that are
continually being updated is crucial
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Cost Considerations
•

COVID-19 has had an incredible financial impact
worldwide

•

Widespread distribution of the COVID-19 vaccine is one
step towards returning to a state of “normal,” which
would allow many operations and industries to return to
the level of financial independence they experienced
prior to the COVID-19 pandemic

•

Patient education is critical for distribution of the
vaccine, especially as it does not have the same level of
efficacy and safety data or history as other vaccines
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Perspective
•

Umair Malik, MD (community
member and physician at NCPC)
 Healthcare providers are facing
information distributed on platforms
that many people trust (Facebook,
Instagram influencers) with
information that we cannot assure is
100% true
 Inherent uncertainty makes it difficult
to make assertive claims about benefits
of the vaccine
 Physicians have a duty to debunk false
information that patients believe, or at
least present evidence-based
information
 All of this must be done in a 15 minute
visit during which other medical
conditions must be addressed as well

•

Robert Wilson (community member
and board member of North Country
Hospital)
 It is important to get information out
on multiple levels, including targeting
various age groups, education levels,
and medical conditions; this can be
done all in one deliverable but must be
clear and concise
 Key information to include: a basic
explanation of how the vaccine works,
who it is safe for, and addressing the
question of if the vaccine can infect
patients with COVID
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Intervention &
Methodology
•

In collaboration with Zeynep Tek, MS3 a handout was created with many
frequently asked questions about the
COVID-19 vaccine identified by
physicians and nurses

•

State-specific information about
vaccine distribution schedule was
included on the back of the handout

•

Claudia Russell, MS-3 developed
surveys about patient thoughts on the
vaccine that were distributed at three
different sites in Vermont and
Connecticut
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Survey Results
•

•

51 Surveys were collected across three
different sites in South Burlington
(VT), Newport (VT), and Ridgefield
(CT)
Ages of participants:






18-29: 1 (2%)
30-49: 11 (21.5%)
50-64: 18 (35.3%)
65-79: 16 (31.4%)
80+: 5 (9.8%)

•

Gender: 23 participants were male
(45.1%), 28 were female (54.9%)

•

Of those surveyed, 40 said they would
receive the vaccine (78.4%), 2 said
they would not receive the vaccine
(3.9%), and 9 were unsure (17.7%)

•

When asked about why patients
would not receive the vaccine, the
following responses were collected:
I don’t want it: 1
I worry I will get sick from it: 2
I worry about long term side effects: 6
I need more information: 5
I don’t trust the vaccine: 2
Other answers: 5
Too many allergies: 3
I don’t trust the vaccine up to 10 years
coming out
 I think it was rushed to be made
 I want to wait
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Effectiveness & Limitations
•

The effectiveness of this deliverable has not yet been evaluated on a largescale

•

Proposed methods to evaluate this project:
 Interviewing physicians and nurses before and after distribution of the handout to
determine if it has decreased the amount of time discussing the COVID-19 vaccine
 Interviewing patients before and after distribution of the handout to determine if
they feel they are better able to make an informed decision about the vaccine when
it becomes offered to them

•

Limitations of this project:
 Information that continues to change and evolve, creating the possible need to
update the handout
 Handout has only been developed in English
 Distribution is currently limited to in-office, and making it more widespread could
involve time and money for administration to reach patients that rely on physical
mail
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Recommendations for Future
Interventions
•

Distribute handout at more practices across Vermont

•

Update handout with most accurate and current information available

•

Analyze effectiveness using the methods outlined previously

•

Interview patients about the data they are most curious and concerned
about regarding the COVID-19 vaccine

•

Write an editorial for local newspapers regarding information on the vaccine
to reach a broader population
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